Biweekly multidose regimen versus once-daily regimen of ofloxacin in patients with repeated acute exacerbations of chronic respiratory tract infections

Akira Watanabe, Masakichi Motorniya, Kiyoshi Konno, Tsukasa Yoshida, Kenichi Takeuchi, Toshiharu Ito, Yushi Nakai, Junichi Saito, Hideo Arai, Chieko Inoue, Masahiro Sakamoto, Tetsuko Ishikawa, Takashi Matsuda, Yoshiyuki Anzai, Tomohiko Iketani, Izumi Hayashi, Toshio Nakamura, Hideo Togashi, Shigeo Takizawa, Kotaro Oizumi

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)

    Abstract

    Two different oral ofloxacin (OFLX) regimens, a biweekly multidose regimen with 3×200 mg/day (regimen A) and a daily single-dose regimen with 200 mg (regimen B), were compared to evaluate the efficacy of new quinolone regimens in controlling acute exacerbations of chronic respiratory tract infections. Fifty-seven patients consisting of 19 with bronchiectasis, 18 with chronic pulmonary emphysema, 10 with chronic bronchitis, 5 with old pulmonary tuberculosis, 4 with diffuse pan-bronchiolitis and one with multiple pulmonary bullae, were evaluated in this study: 26 in regimen A and 31 in regimen B. The corrected mean incidence of exacerbations per case during six months before and during the study was reduced from 2.66 to 0.95 in regimen A, and from 2.55 to 0.59 in regimen B, both statistically significant differences. As therapy of acute exacerbations during the study, injection therapy on admission was required in most cases of regimen A. On the other hand, simply increasing the ofloxacin dose given in the outpatient clinic managed to control acute exacerbations in most cases of regimen B. The development of resistant strains was not clinically important because only one of 12 strains of Pseudomonas aeruginosa that had been isolated continuously during the study acquired a certain degree of resistance to ofloxacin when tested by the sensitivity disk. Adverse reactions were found in 4 patients in regimen A and in 2 in regimen B, these were mainly sleep disturbance and dizziness. We conclude that the longterm administration of new quinolones, especially the daily single-dose regimen with 200 mg of ofloxacin, is useful in controlling acute exacerbations of chronic repiratory tract infections.

    Original languageEnglish
    Pages (from-to)639-646
    Number of pages8
    JournalChemotherapy
    Volume42
    Issue number5
    DOIs
    Publication statusPublished - 1994 Jan 1

    Keywords

    • onoxacin

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Biweekly multidose regimen versus once-daily regimen of ofloxacin in patients with repeated acute exacerbations of chronic respiratory tract infections'. Together they form a unique fingerprint.

    Cite this